Browse > Article

Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients  

Cecener, Gulsah (Department of Medical Biology, Medical Faculty, Uludag University)
Ak, Secil (Department of Medical Biology, Medical Faculty, Uludag University)
Eskiler, Gamze Guney (Department of Medical Biology, Medical Faculty, Uludag University)
Demirdogen, Elif (Department of Medical Biology, Medical Faculty, Uludag University)
Erturk, Elif (Department of Medical Biology, Medical Faculty, Uludag University)
Gokgoz, Sehsuvar (Department of General Surgery, Medical Faculty, Uludag University)
Polatkan, Volkan (Department of General Surgery, Medical Faculty, Uludag University)
Egeli, Unal (Department of Medical Biology, Medical Faculty, Uludag University)
Tunca, Berrin (Department of Medical Biology, Medical Faculty, Uludag University)
Tezcan, Gulcin (Department of Medical Biology, Medical Faculty, Uludag University)
Topal, Ugur (Department of Radiology, Medical Faculty, Uludag University)
Tolunay, Sahsine (Department of Pathology, Medical Faculty, Uludag University)
Tasdelen, Ismet (Department of General Surgery, Medical Faculty, Uludag University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.9, 2016 , pp. 4241-4246 More about this Journal
Abstract
Background: Dysregulation of miRNA expression may be used as a biomarker for specific tumours because it may contribute to development of cancer. Circulating miRNA profiles have been highlighted for their potential as predictive markers in heterogeneous diseases such as breast cancer. In the literature, there is evidence that miR-195 levels are differentially expressed pre- and post-operative periods in breast cancer patients. At the same time, miRNA expression levels may vary because of ethnic origins. This study aimed to determine expression levels and potential roles of miR-195 in Turkish breast cancer patients. Materials and Methods: The expression patterns of miR-195 were initially examined in breast cancer tissues (luminal A and B type) (n=96). Subsequently, blood samples were prospectively collected from preoperative and postoperative Turkish breast cancer patients and disease free controls. Total RNA was isolated, and the expression level of miR-195 was quantified by real-time PCR. Results: We found that miR-195 level was altered in Turkish breast cancer patients, with down-regulation evident in breast cancer tissues compared to normal adjacent specimens. Furthermore, circulating levels of miR-195 was significantly decreased in post-operative blood samples compared with pre-operative levels (p=0.01 and <0.05). However, miR-195 was significantly increased in pre-operative blood samples of the luminal B type (p=0.04 and <0.05). Conclusions: This study represents the first report of a miR-195 expression profile in Turkish breast cancer patients. Our data suggests that miR-195 levels might be a clinically useful biomarker in the earliest stage of Turkish breast cancer patients.
Keywords
Circulating miRNA; miR-195; breast cancer patients; Turkey;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Kayani MR, Kayani MA, Malik FA et al (2011). Role of miRNAs in breast cancer. Asian Pacific J Cancer Prev, 12, 3175-80.
2 Kosaka N, Iguchi H, Ochiya T, (2010). Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci, 101, 2087-92.   DOI
3 Livak KJ, Schmittgen T.D, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2- ${\Delta}{\Delta}CT$) method. Methods, 25, 402-8.   DOI
4 Lowery AJ, Miller N, McNeill RE, et al (2008). MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res, 14, 360-5.   DOI
5 Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8.   DOI
6 Kavitha N, Vijayarathna S, Jothy SL, et al (2014). MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev, 15, 7489-97.   DOI
7 Madhavan D, Cuk K, Burwinkel B, et al (2013). Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. FGENE, 4.
8 Luo Q, Wei C, Li X, et al (2014). MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Reps, 31, 1096-102.   DOI
9 Ma R, Jiang T, Kang X (2012). Circulating microRNAs in cancer: origin, function and application. JECCR, 31, 38.
10 Ma R, Jiang T, Kang X (2012). Circulating microRNAs in cancer: origin, function and application. J Exp Clin Can, 31, 38.   DOI
11 Madhavan D, Zucknick M, Wallwiener M, et al (2012). Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res, 18, 5972-82.   DOI
12 Mirnezami AH, Pickard K, Zhang L, et al (2009). MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol, 3, 339-47.
13 Shavers VL, Brown ML, (2002). Racial and ethnic disparities in the receipt of cancer treatment. J National Cancer Inst, 94, 334-57.   DOI
14 Allegra A, Alonci A, Campo S, et al (2012). Circulating microRNA: New biomarkers in diagnosis, prognosis and treatment of cancer. Int J Oncol, 41, 1897-912.   DOI
15 Aquilar F, Ramirez JA, Malagon-Santiago I, et al (2013). Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Disease Markers, 34, 163-169.   DOI
16 Qu H, Xu W , Huang Y et al (2011). Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev, 12, 1117-25.
17 Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12.
18 Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12, 90.   DOI
19 Sarfati D, Blakely T, Shaw C, et al (2006). Patterns of disparity: ethnic and socio-economic trends in breast cancer mortality in New Zealand. Cancer Causes Control, 17, 671-8.   DOI
20 Schrauder MG, Strick R, Schulz-Wendtland R, et al (2012). Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One, 7, 1-9.
21 Shavers VL, Brown M.L, (2002). Racial and ethnic disparities in the receipt of cancer treatment. J National Cancer Inst, 94, 334-57.   DOI
22 Shen J, Ambrosone CB, DiCioccio RA, et al (2008). A functional polymorphism in the miR-146a gene and age of familialbreast/ovarian cancer diagnosis. Carcinogenesis, 29, 1963-66.   DOI
23 Si H, Sun X, Chen Y, et al (2013). Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol, 139, 223-9.   DOI
24 Sun Y, Wang M, Lin G, et al (2012). Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One, 7.
25 Uchida N, Suda T, et al (2013). Effect of chemotherapy for Luminal A breast cancer. Acta Med, 56, 51-6.
26 Chen G, Wang J, Cui Q, (2013). Could circulating miRNAs contribute to cancer therapy? Trends Mol Med, 19, 71-3.   DOI
27 Asaga S, Kuo C, Nguyen T, et al (2011). Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem, 57, 84-91.   DOI
28 Calin GA, Croce CM, (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6, 857-66.   DOI
29 Chan M, Liaw CS, Ji SM, (2013). Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res, 19, 4477-87.   DOI
30 Corcoran C, Friel AM, Duffy MJ, et al (2011). Intracellular and extracellular MicroRNAs in breast cancer. Clin Chem, 57, 18-32.   DOI
31 Cortez MA, Welsh JW, Calin GA, (2012). Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res, 195, 151-61.
32 Creighton CJ, (2012). The molecular profile of luminal B breast cancer. Biologics: Targets Therapy, 6, 289-97.
33 Cuk K, Zucknick M, Heil J, et al (2013). Circulating micrornas in plasma as early detection markers for breast cancer. Int J Cancer, 132, 1602-12.   DOI
34 Demirdogen Sevinc E, Egeli U, Cecener G, et al (2015). Association of miR-1266 with Recurrence/Metastasis Potential in Estrogen Receptor Positive Breast Cancer. Asian Pac J Cancer Prev, 16, 291-7   DOI
35 Desantis C, Ma J, Bryan L, et al (2014). Breast cancer statistics. CA Cancer J Clin, 64, 52-62.   DOI
36 EK Ng, Li R, Shin VY, et al (2013). Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One, 8, 531-41.
37 Wiencke JK (2004). Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer, 4, 79-84.   DOI
38 Vasudevan S, Tong YC, Steitz JA, (2007). Switching from repression to activation: MicroRNAs can up-regulate translation. Sci, 318, 1931-34.   DOI
39 Wang H, Tan G, Dong L, et al (2012). Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One, 7.
40 Wang J, Zhang K, Liu S, et al (2014). Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules, 19, 1912-38.   DOI
41 Wu Q, Lu Z, Li H, et al (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol.
42 Wu X, Somlo G, Yu Y, et al (2012). De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med, 10, 42.   DOI
43 Yanagawa M, Ikemot K, Kawauchi S, et al (2012). Luminal A and Luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotypes. BMC Research Notes, 5, 376.   DOI
44 Zhang H, Su B, Zhou QM, et al (2009). Differential expression
45 Heneghan HM, Miller N, Kelly R, et al (2010). Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist, 15, 673-82.   DOI
46 Erturk E, Cecener G, Egeli U, et al (2014). Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Mol Cell Biochem, 395, 77-88.   DOI
47 Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics, 9, 102-14.   DOI
48 He L, Hannon GJ (2004). MicroRNAs: Small RNAs with a big role in gene regulation. Nature Rev Genet, 5, 522-31.   DOI
49 Heneghan HM, Miller N, Kerin MJ, (2011). Circulating microRNAs: promising breast cancer biomarkers. Breast Cancer Res, 13, 402.   DOI
50 Heneghan HM, Miller N, Lowery AJ, et al (2010). Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg, 251, 499-505.   DOI
51 Iorio MV, Casalini P, Tagliabue E, et al (2008). MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. European J Cancer, 44, 2753-9.   DOI
52 Iorio MV, Ferracin M, Liu CG, (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.   DOI
53 Jack RH, Davies EA, Renshaw C, et al (2013). Differences in breast cancer hormone receptor status in ethnic groups: A London population. Eur J Cancer, 49, 696-702.   DOI